Stock listing
NASDAQ:ARTV Artiva Biotherapeutics, Inc. Stock
Home listing (NASDAQ) of Artiva Biotherapeutics, Inc.
Follow Artiva Biotherapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ARTV
$3.78 USD +0.01 (+0.3%)
Close on Nov 20, 2026
- Day range
- $3.77 – $3.93 USDNov 20, 2026
- Volume
- 1.78M sharesNov 20, 2026
- Market cap
- $186.9M USDAt the close on Nov 20, 2026 · price × 49.43M shares outstanding
- 52-week range
- $2.96 – $14.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.45M USDMedian day 473,192 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ARTV · Home | $3.78 USD | +0.01 (+0.3%) | 1,775,377 | $3.82 | $3.93 | $3.77 | $3.77 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARTV · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.78 | +0.01 | +0.3% | $3.82 | $3.93 | $3.77 | 1,775,377 | |
| $3.77 | -0.09 | -2.3% | $3.875 | $3.94 | $3.75 | 972,615 | |
| $3.86 | -0.10 | -2.5% | $3.95 | $3.99 | $3.81 | 1,403,652 | |
| $3.96 | -0.05 | -1.2% | $3.98 | $4.065 | $3.925 | 1,311,979 | |
| $4.01 | +0.05 | +1.3% | $4.00 | $4.035 | $3.905 | 868,508 | |
| $3.96 | -0.11 | -2.7% | $4.05 | $4.095 | $3.93 | 1,436,864 | |
| $4.07 | +0.01 | +0.2% | $4.10 | $4.13 | $4.045 | 870,853 | |
| $4.06 | -0.16 | -3.8% | $4.19 | $4.22 | $4.04 | 925,853 | |
| $4.22 | +0.07 | +1.7% | $4.20 | $4.255 | $4.14 | 939,951 | |
| $4.15 | +0.02 | +0.5% | $4.16 | $4.24 | $4.13 | 908,723 | |
| $4.13 | -0.09 | -2.1% | $4.19 | $4.22 | $4.07 | 976,833 | |
| $4.22 | +0.02 | +0.5% | $4.25 | $4.28 | $4.16 | 754,021 | |
| $4.20 | +0.01 | +0.2% | $4.24 | $4.25 | $4.155 | 623,313 | |
| $4.19 | 0.00 | 0.0% | $4.21 | $4.24 | $4.14 | 938,152 | |
| $4.19 | -0.04 | -0.9% | $4.20 | $4.26 | $4.10 | 1,966,165 | |
| $4.23 | -0.045 | -1.1% | $4.22 | $4.27 | $4.153 | 1,890,513 | |
| $4.275 | +0.005 | +0.1% | $4.35 | $4.39 | $4.22 | 2,884,135 | |
| $4.27 | -1.89 | -30.7% | $4.25 | $4.45 | $4.00 | 8,673,746 | |
| $6.16 | +0.01 | +0.2% | $6.15 | $6.25 | $5.95 | 487,078 | |
| $6.15 | -0.05 | -0.8% | $6.16 | $6.17 | $5.95 | 315,489 | |
| $6.20 | -0.29 | -4.5% | $6.38 | $6.65 | $6.16 | 393,902 | |
| $6.49 | -0.07 | -1.1% | $6.60 | $6.74 | $6.44 | 363,943 | |
| $6.56 | +0.67 | +11.4% | $5.89 | $6.65 | $5.86 | 449,925 | |
| $5.89 | +0.04 | +0.7% | $5.97 | $6.20 | $5.76 | 536,922 | |
| $5.85 | -0.21 | -3.5% | $6.08 | $6.10 | $5.82 | 573,256 | |
| $6.06 | +0.15 | +2.5% | $5.93 | $6.16 | $5.85 | 478,246 | |
| $5.91 | -0.38 | -6.0% | $6.21 | $6.25 | $5.88 | 707,557 | |
| $6.29 | -0.48 | -7.1% | $6.74 | $6.74 | $6.236 | 526,968 | |
| $6.77 | -0.17 | -2.4% | $6.92 | $6.943 | $6.73 | 248,580 | |
| $6.94 | +0.14 | +2.1% | $6.84 | $7.135 | $6.77 | 275,938 | |
| $6.80 | -0.20 | -2.9% | $6.89 | $6.92 | $6.575 | 339,711 | |
| $7.00 | -0.27 | -3.7% | $7.10 | $7.27 | $6.84 | 324,576 | |
| $7.27 | +0.14 | +2.0% | $7.12 | $7.38 | $6.92 | 665,416 | |
| $7.13 | +0.30 | +4.4% | $6.75 | $7.16 | $6.52 | 473,192 | |
| $6.83 | +0.04 | +0.6% | $6.89 | $7.00 | $6.74 | 587,649 | |
| $6.79 | -0.33 | -4.6% | $7.11 | $7.15 | $6.77 | 444,372 | |
| $7.12 | +0.09 | +1.3% | $7.10 | $7.40 | $6.96 | 383,976 | |
| $7.03 | -0.02 | -0.3% | $7.06 | $7.18 | $6.92 | 450,565 | |
| $7.05 | +0.06 | +0.9% | $6.91 | $7.185 | $6.75 | 437,532 | |
| $6.99 | -0.50 | -6.7% | $7.48 | $7.49 | $6.90 | 507,137 | |
| $7.49 | -0.23 | -3.0% | $7.62 | $7.71 | $7.22 | 511,722 | |
| $7.72 | -0.37 | -4.6% | $7.99 | $8.20 | $7.52 | 407,794 | |
| $8.09 | +0.26 | +3.3% | $7.87 | $8.39 | $7.855 | 437,976 | |
| $7.83 | -0.78 | -9.1% | $8.63 | $8.64 | $7.78 | 629,415 | |
| $8.61 | +0.17 | +2.0% | $8.45 | $8.75 | $8.40 | 2,208,401 | |
| $8.44 | -0.16 | -1.9% | $8.66 | $8.72 | $8.35 | 456,517 | |
| $8.60 | -0.31 | -3.5% | $8.89 | $9.03 | $8.485 | 516,987 | |
| $8.91 | -1.23 | -12.1% | $10.05 | $10.05 | $8.84 | 584,582 | |
| $10.14 | -0.08 | -0.8% | $10.21 | $10.55 | $10.13 | 243,866 | |
| $10.22 | -0.20 | -1.9% | $10.49 | $10.61 | $10.10 | 228,437 | |
| $10.42 | -0.37 | -3.4% | $10.70 | $10.93 | $10.36 | 449,476 | |
| $10.79 | -0.09 | -0.8% | $10.78 | $11.15 | $10.73 | 325,338 | |
| $10.88 | -0.31 | -2.8% | $10.83 | $11.16 | $10.70 | 211,697 | |
| $11.19 | +0.065 | +0.6% | $11.02 | $11.34 | $10.94 | 168,592 | |
| $11.13 | -0.185 | -1.6% | $11.34 | $11.35 | $10.98 | 365,624 | |
| $11.31 | +0.03 | +0.3% | $11.26 | $11.51 | $11.05 | 306,518 | |
| $11.28 | -0.02 | -0.2% | $11.00 | $11.36 | $10.88 | 268,855 | |
| $11.30 | +0.21 | +1.9% | $11.01 | $11.35 | $10.88 | 249,844 | |
| $11.09 | -0.85 | -7.1% | $11.78 | $11.80 | $11.00 | 223,493 | |
| $11.94 | +0.17 | +1.4% | $11.72 | $12.08 | $11.56 | 218,273 | |
| $11.77 | 0.00 | 0.0% | $11.75 | $11.93 | $11.60 | 262,556 | |
| $11.77 | +0.25 | +2.2% | $11.60 | $11.91 | $11.53 | 266,361 | |
| $11.52 | +0.59 | +5.4% | $10.83 | $11.70 | $10.49 | 307,236 | |
| $10.93 | -0.21 | -1.9% | $11.26 | $11.60 | $10.76 | 199,424 | |
| $11.14 | -0.56 | -4.8% | $11.50 | $11.58 | $10.93 | 319,084 |
- Ticker
- NASDAQ:ARTV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 27, 2026
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Latest deck · Sep 23, 2026
17th International Symposium on Sjögren's Disease 2026
Conference · 18 slides
Latest news
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Oct 27, 2026
Closed $4.27 (-30.7%) on Oct 27, 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Oct 2, 2026
Closed $6.83 (+0.6%) on Oct 2, 2026
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Oct 1, 2026
Closed $6.79 (-4.6%) on Oct 1, 2026
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Sep 23, 2026
Closed $7.72 (-4.6%) on Sep 23, 2026
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 17, 2026
Closed $8.44 (-1.9%) on Sep 17, 2026
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Sep 8, 2026
Closed $10.88 (-2.8%) on Sep 8, 2026
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
Sep 2, 2026
Closed $11.31 (+0.3%) on Sep 2, 2026
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 6, 2026
Closed $11.27 (-2.7%) on Aug 7, 2026
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2026
Closed $9.76 (+8.0%) on Jul 17, 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 23, 2026
Closed $9.32 (-4.9%) on Jun 24, 2026
Artiva Biotherapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 39 in all · newest Oct 27, 2026 · oldest 2024
- Decks
- 7 decks · latest Sep 23, 2026
Where Artiva Biotherapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ARTV · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ARTV | BOATS | United States | USD |
Valuation
Price/book 0.6× against a median of 2.5×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$123.1M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| SillaJen, Inc. · KRX:215600 | US$193.5M | US$141.7M | n/a | 17.6× | n/a | 2.6× | −223.8% | 0.0× | n/a |
| AN2 Therapeutics, Inc. · NASDAQ:ANTX | US$192.8M | US$128.4M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.54 |
| Cartesian Therapeutics, Inc. · NASDAQ:RNAC | US$187.3M | US$114.5M | n/a | 112× | n/a | n/a | n/a | n/a | 1.23 |
| Inventage Lab, Inc. · KRX:389470 | US$185.9M | US$113.3M | n/a | 61.3× | n/a | 2.8× | −127.0% | 0.2× | n/a |
| Inhibikase Therapeutics, Inc. · NASDAQ:IKT | US$185.2M | −US$8.17M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.50 |
| Antengene Corporation Limited · HKEX:6996 | US$183.1M | US$107.1M | n/a | 6.8× | n/a | 1.3× | −227.0% | 0.3× | n/a |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.7M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Median of the others | US$185.5M | US$113.9M | 17.6× | 2.5× | −222.8% | 0.0× | 1.29 |
Forecasts
2 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.64 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Fred Aslan | Chief Executive Officer |
| Thad Huston | Chief Financial Officer and Award of Inducement Grant |
| Jennifer Bush | Chief Operating Officer |
| Adria Carbo | VP, Business Development |
| Benjamin Dewees | SVP, Regulatory Affairs |
| Cliff Wallace | VP, Quality |
| David Moriarty | SVP, Clinical Operations |
| Feng Xu | SVP, Biometrics |
| Heather Raymon | SVP, Research & Early Development |
| Ilias Alevizos | VP, Clinical Development |
| John O’Neil | VP, Finance |
| Larry Kovalick | VP, Medical Affairs |
| Nicholas Veomett | VP, Corporate Development |
| Sara Mills | Vice President, AlloNK® Program Leader |
| Christopher Horan | Chief Technical Operations Officer |
| Subhashis Banerjee | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Diego Miralles | Director |
| Elaine Sorg | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −3.8% |
| Q2 2026 | Aug 6, 2026 · After close | −2.7% |
| Q1 2026 | May 8, 2026 · Before open | −13.0% |
| Q4 2025 | Mar 30, 2026 | +28.5% |
| Q3 2025 | Nov 12, 2025 · Before open | +10.9% |
| Q2 2025 | Aug 7, 2025 · Before open | −8.0% |
| Q1 2025 | May 8, 2025 · Before open | +3.8% |
| Q4 2024 | Mar 24, 2025 | −6.6% |
| Q3 2024 | Nov 12, 2024 · After close | −10.5% |
| Q2 2024 | Aug 29, 2024 · After close | +2.1% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 29, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 17th International Symposium on Sjögren's Disease 2026 | Conference | 18 slides | Sep 23, 2026 |
| Post-EULAR Virtual Webcast (June 2026) | Conference | 37 slides | Jun 8, 2026 |
| EULAR 2026 | Conference | 15 slides | Jun 6, 2026 |
| EULAR 2026 | Conference | 15 slides | Jun 3, 2026 |
| Investor Presentation (May 2026) | Investor deck | 33 slides | May 2026 |
| Corporate Update (November 2025) | Corporate update | 30 slides | Nov 12, 2025 |
| Investor Presentation (August 2024) | Investor deck | 21 slides | August 2024 |
IPO
Priced at US$12.00 a share on Jul 18, 2024.
- Price
- US$12.00 a share
- Shares offered
- 13,920,000 shares of common stock
- Offering size
- US$167 million
- Underwriters' option
- Up to 2,088,000 more shares
- Underwriters
- Jefferies, TD Cowen, Cantor, Wedbush PacGrow, Needham & Company · In the order on the cover
- Shares delivered
- On or about Jul 22, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 3, 2024 |
| Filed publicly | Jun 28, 2024 |
| Amended once | Jul 15, 2024 |
| Shares registered with an exchange | Jul 16, 2024 |
| Declared effective by the SEC | Jul 18, 2024 |
| Final prospectus, with the price | Jul 22, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 22, 2024 |
| EFFECT · Notice that a registration is effective | Jul 18, 2024 |
| S-1MEF · Registration of more shares for the same offering | Jul 18, 2024 |
| CERT · Exchange's certificate of listing | Jul 18, 2024 |
| CORRESP · Letter to the SEC | Jul 16, 2024 |
| CORRESP · Letter to the SEC | Jul 16, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 16, 2024 |
| S-1/A · Registration statement, amended | Jul 15, 2024 |
| CORRESP · Letter to the SEC | Jul 5, 2024 |
| CORRESP · Letter to the SEC | Jun 28, 2024 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jun 28, 2024 |
| UPLOAD · Letter from the SEC | Jun 21, 2024 |
| DRS/A · Draft registration statement, amended | Jun 10, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jun 7, 2024 |
| UPLOAD · Letter from the SEC | May 30, 2024 |
| DRS · Draft registration statement | May 3, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 22, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 251.0K | 33.5M | 4.93M | 2.00M | 0 |
| Cost of revenue | 2.60M | |||||
| Gross profit | -2.60M | 251.0K | 33.5M | 4.93M | 2.00M | |
| Research and development | 69.5M | 50.3M | 50.3M | 44.0M | 42.4M | 13.8M |
| Selling, general and administrative | 20.3M | 17.2M | 13.9M | 20.8M | 12.9M | 4.43M |
| Operating income | -89.8M | -67.3M | -30.7M | -59.8M | -53.3M | -18.3M |
| Depreciation and amortization | 2.60M | 2.43M | 2.27M | 1.16M | 248.0K | 73.0K |
| EBITDA | -87.2M | -64.9M | -28.4M | -58.7M | -53.0M | -18.2M |
| Interest expense | 0 | 199.0K | ||||
| Income before tax | 83.9M | -65.4M | -28.6M | -58.3M | -71.8M | -18.0M |
| Income tax | 0 | 0 | 72.0K | 53.0K | -18.6M | 676.0K |
| Net income | -83.9M | -65.4M | -28.7M | -58.4M | -71.8M | -18.0M |
| Earnings per share, basic | -3.43 | -5.81 | -35.78 | -3.32 | -4.08 | -1.02 |
| Earnings per share, diluted | -3.43 | -5.81 | -35.78 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.7M | 40.2M | 53.5M | 102.5M | 160.9M | 25.4M | 1.87M |
| Short-term investments | 81.3M | 145.2M | 23.5M | 0 | |||
| Receivables | 767.0K | 0 | 1.03M | 525.0K | 468.0K | 0 | |
| Current assets | 112.7M | 188.6M | 79.8M | 104.7M | 162.3M | 26.1M | 1.96M |
| Property, plant and equipment | 6.62M | 6.37M | 8.10M | ||||
| Total assets | 130.9M | 209.6M | 105.1M | 133.1M | 169.9M | 29.2M | 4.84M |
| Accounts payable | 355.0K | 1.12M | 614.0K | 1.10M | 1.44M | 2.15M | 258.0K |
| Current liabilities | 13.1M | 12.3M | 12.2M | 25.6M | 19.3M | 5.76M | 942.0K |
| Long-term debt | 5.64M | ||||||
| Total debt | 10.9M | 14.4M | 16.9M | 19.4M | 1.74M | 2.12M | 7.82M |
| Total liabilities | 21.0M | 22.9M | 50.7M | 273.8M | 258.8M | 50.8M | 8.80M |
| Shareholders' equity | 110.0M | 186.6M | -162.0M | -140.7M | -88.9M | -21.6M | -3.96M |
| Shares outstanding | 49.4M | 49.4M | 24.7M | 17.6M | 17.6M | 17.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -76.8M | -55.0M | -47.4M | -50.8M | -15.3M | -13.5M |
| Capital spending | -2.59M | -642.0K | -3.26M | -6.30M | -1.72M | -284.0K |
| Free cash flow | -79.3M | -55.7M | -50.7M | -57.1M | -17.0M | -13.8M |
| Cash from investing | 63.4M | -120.5M | -26.0M | -6.30M | -1.72M | -284.0K |
| Cash from financing | 9.00K | 162.2M | 24.4M | -1.26M | 152.8M | 37.4M |
| Share buybacks | 0 | -4.18M | -12.0K | -5.00K | ||
| Change in cash | -13.3M | -13.3M | -49.0M | -58.4M | 135.7M | 23.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 17, 2026 | Management or board change | SEC |
| 8-K/A · Current report, amended | Nov 9, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 11, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 11, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 10, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Aug 3, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 3, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 22, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 8-K · Current report | May 19, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 8-K · Current report | May 8, 2026 | Current report | SEC |
| 424B5 · Prospectus | May 8, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | May 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Feb 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 11, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 6, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 23, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2025 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 22, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 3, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 29, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 29, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Aug 1, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 1, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 1, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jul 29, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jul 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Jul 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jul 22, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2024 | Current report | SEC |
| 424B4 · Prospectus | Jul 19, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 19, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Jul 18, 2024 | Insider trade | SEC |
This page holds 200 of 240 filings. Open Filings
Cap table
Built by 6ix from Artiva Biotherapeutics, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 49,432,351
- Fully diluted
- 49,432,351
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 49,432,351 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 49,432,351 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Jul 18, 2024 |
| Daniel Baker Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Cue Biopharma, Inc. (CHIEF DEVELOPMENT OFFICER · Since at least Nov 25, 2024) | Director · Since at least Jan 28, 2025 |
| Elizabeth L. Hougen Other companies: Ionis Pharmaceuticals, Inc. (Executive Vice President, Chief Financial Officer · Since at least Jan 1, 2013); Akcea Therapeutics Inc (Chief Financial Officer · Jul 13, 2017 – Jul 13, 2017 · Past) | Director · Since at least Jul 18, 2024 |
| Peter Kolchinsky Other companies: Vor Biopharma Inc. (Director · Since at least Apr 2, 2026); ARS Pharmaceuticals, Inc. (Director · Since at least Sep 30, 2025) | Director · Since at least Jun 12, 2026 |
| Alison Moore Other companies: Codexis, Inc. (President and CEO, Director · Since at least Oct 13, 2025) | Director · Since at least Jun 24, 2025 |
| Diego Miralles Other companies: Contineum Therapeutics, Inc. (President and Head of Research and Development, Artiva Biotherapeutics, Inc. · Since at least Mar 17, 2025) | Director · Since at least Aug 6, 2026 |
| Gines Diego Miralles Other companies: Contineum Therapeutics, Inc. (Director · Since at least Jun 26, 2025) | President & Head of R&D · Since at least Jun 24, 2025 |
| Thad Huston Other companies: LivaNova PLC (Chief Financial Officer · May 20, 2017 – May 23, 2020 · Past) | Chief Financial Officer and Award of Inducement Grant · Since at least Feb 18, 2026 |
| Adria Carbo | VP, Business Development · Since at least Nov 5, 2026 |
| Benjamin Dewees | SVP, Regulatory Affairs · Since at least Nov 5, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Christopher Horan | Chief Technical Operations Officer · Since at least Jul 18, 2024 |
| Cliff Wallace | VP, Quality · Since at least Nov 4, 2026 |
| David Moriarty | SVP, Clinical Operations · Since at least Nov 5, 2026 |
| Elaine Sorg | Director · Since at least Feb 19, 2026 |
| Feng Xu | SVP, Biometrics · Since at least Nov 5, 2026 |
| Fred Aslan | Chief Executive Officer · Since at least Oct 27, 2026 |
| Heather Raymon | SVP, Research & Early Development · Since at least Jul 18, 2024 |
| Ilias Alevizos | VP, Clinical Development · Since at least Nov 5, 2026 |
| Jennifer Bush | COO, CLO, Compliance Officer · Since at least Jul 18, 2024 |
| John O’Neil | VP, Finance · Since at least Nov 5, 2026 |
| Larry Kovalick | VP, Medical Affairs · Since at least Nov 4, 2026 |
| Nicholas Veomett | VP, Corporate Development · Since at least Nov 5, 2026 |
| Sara Mills | Vice President, AlloNK® Program Leader · Since at least Nov 5, 2026 |
| Subhashis Banerjee | Chief Medical Officer · Since at least Apr 8, 2025 |
| Yong-Jun Huh | Director · Jul 18, 2024 – Jul 22, 2024 · Past |
Log in to ask 6ix AI your own questions about Artiva Biotherapeutics, Inc.